TY - JOUR
TI - Clinical study of hyperglycemia and SARS-CoV-2 infection in intensive care unit patients
AU - ILIAS, I.
AU - JAHAJ, E.
AU - KOKKORIS, S.
AU - ZERVAKIS, D.
AU - TEMPERIKIDIS, P.
AU - MAGIRA, E.
AU - PRATIKAKI, M.
AU - VASSILIOU, A.G.
AU - ROUTSI, C.
AU - KOTANIDOU, A.
AU - DIMOPOULOU, I.
JO - In vivo (Athens, Greece)
PY - 2020
VL - 34
TODO - 5
SP - 3029-3032
PB - International Institute of Anticancer Research
SN - null
TODO - 10.21873/invivo.12136
TODO - glucose;  short acting insulin;  insulin, adult;  Article;  artificial ventilation;  blood glucose monitoring;  clinical article;  clinical trial;  coronavirus disease 2019;  critical illness;  critically ill patient;  disease course;  female;  glucose blood level;  hospital mortality;  human;  hyperglycemia;  hypoxemia;  insulin treatment;  length of stay;  male;  medical intensive care unit;  nonhuman;  respiratory failure;  Severe acute respiratory syndrome coronavirus 2;  stress;  Betacoronavirus;  complication;  Coronavirus infection;  diabetes mellitus;  genetics;  hospitalization;  hyperglycemia;  intensive care unit;  metabolism;  middle aged;  pandemic;  pathogenicity;  pathophysiology;  respiratory failure;  severe acute respiratory syndrome;  virology;  virus pneumonia, Betacoronavirus;  Blood Glucose;  Coronavirus Infections;  Diabetes Mellitus;  Female;  Hospitalization;  Humans;  Hyperglycemia;  Insulin;  Intensive Care Units;  Male;  Middle Aged;  Pandemics;  Pneumonia, Viral;  Respiration, Artificial;  Respiratory Insufficiency;  Severe Acute Respiratory Syndrome
TODO - Background/Aim: Reports indicate that coronaviridae may inhibit insulin secretion. In this report we aimed to describe the course of glycemia in critically ill patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Patients and Methods: We studied 36 SARS-CoV-2 patients (with no history of diabetes) in one intensive care unit (ICU). All the patients were admitted for hypoxemic respiratory failure; all but four required mechanical ventilation. The mean (±SD) age of the patients was 64.7 (9.7) years; 27 were men; the mean (±SD) duration of ICU stay was 12.9 (8.3 days). Results: Twenty of 36 patients presented with hyperglycemia; brief intravenous infusions of short-acting insulin were administered in six patients. As of May 29 2020, 11 patients had died (seven with hyperglycemia). In 17 patients the Hyperglycemia Index [HGI; defined as the area under the curve of (hyper)glycemia level time (h) divided by the total time in the ICU] was <16.21 mg/dl (0.90 mmol/l), whereas in three patients the HGI was ≥16.21 mg/dl (0.90 mol/l) and <32.25 mg/dl (1.79 mmol/l). Conclusion: In our series of ICU patients with SARS-CoV-2 infection, and no history of diabetes, a substantial number of patients had hyperglycemia, to a higher degree than would be expected by the stress of critical illness, lending credence to reports that speculated a tentative association between SARS-CoV-2 and hyperglycemia. This finding is important, since hyperglycemia can lead to further infectious complications. © 2020 International Institute of Anticancer Research. All rights reserved.
ER -